Dr. Brett King is Associate Professor of Dermatology, specializing in skin diseases recalcitrant to first-line therapies. He has pioneered the use of Janus kinase (JAK) inhibitors in cutaneous diseases, in particular for alopecia areata, vitiligo, and atopic dermatitis, in addition to other disorders. He sees patients at Yale Dermatology-Middlebury.

Dr. King provides care of patients with all dermatologic conditions, with special interest in:

• atopic dermatitis (eczema)
• alopecia areata
• vitiligo
• sarcoidosis
• granuloma annulare
• pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, and other autoimmune blistering diseases
• morphea, systemic sclerosis (scleroderma)
• pruritus (itch)
• Stevens-Johnson syndrome, toxic epidermal necrolysis

He is experienced with the use of systemic medications including retinoids, methotrexate, cyclosporine, azathioprine (Imuran®), mycophenolate mofetil (Cellcept®), tofacitinib (Xeljanz®), ruxolitinib (Jakafi®), apremilast (Otezla®), and the ‘biologics’ (e.g. etanercept (Enbrel®), adalimumab (Humira®), infliximab (Remicade®), ustekinumab (Stelara®), sekucinumab (Cosentyx®), ixekizumab (Taltz®), IVIG, and rituximab (Rituxan®)), as well as phototherapy.

Dr. King received his B.A. at the University of California at Santa Cruz, his Ph.D. from Stanford University and his M.D. from Yale University School of Medicine. He completed medical internship at Massachusetts General Hospital and dermatology residency at Yale University School of Medicine.